Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs.

Kolovos S, Nador G, Kishore B, Streetly M, Rabin NK, Chantry AD, Yong K, Ashcroft J, Bowcock S, Drayson MT, Ramasamy K, Prieto-Alhambra D, Cooper C, Javaid MK, Pinedo-Villanueva R.

J Bone Oncol. 2019 Jun 7;17:100243. doi: 10.1016/j.jbo.2019.100243. eCollection 2019 Aug.

2.

Risk of relapse of multiple myeloma following kidney transplantation.

Shah S, Ibrahim M, Delaney M, Schey S, Bygrave C, Streetly M, Benjamin R.

Clin Kidney J. 2019 Jan 25;12(2):216-223. doi: 10.1093/ckj/sfy137. eCollection 2019 Apr.

3.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.

Brighton TA, Khot A, Harrison SJ, Ghez D, Weiss BM, Kirsch A, Magen H, Gironella M, Oriol A, Streetly M, Kranenburg B, Qin X, Bandekar R, Hu P, Guilfoyle M, Qi M, Nemat S, Goldschmidt H.

Clin Cancer Res. 2019 Jul 1;25(13):3772-3775. doi: 10.1158/1078-0432.CCR-18-3470. Epub 2019 Mar 19.

PMID:
30890552
4.

Added Value of Contrast-Enhanced T1-Weighted and Diffusion-Weighted Sequences for Characterization of Incidental Findings on Whole Body Magnetic Resonance Imaging in Plasma-Cell Disorders.

Westerland O, Sivarasan N, Natas S, Verma H, McElroy S, Winfield JM, Neji R, El-Najjar I, Kazmi M, Streetly M, Goh V.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):822-828. doi: 10.1016/j.clml.2018.08.006. Epub 2018 Aug 13.

5.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K.

Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4.

6.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.

Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.

7.

Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).

Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.

Br J Haematol. 2019 May;185(3):573-578. doi: 10.1111/bjh.15551. Epub 2018 Aug 20. No abstract available.

8.

National survey of imaging practice for suspected or confirmed plasma cell malignancies.

Westerland OA, Pratt G, Kazmi M, El-Najjar I, Streetly M, Yong K, Morris M, Mehan R, Sambrook M, Hall-Craggs M, Silver D, Goh V.

Br J Radiol. 2018 Dec;91(1092):20180462. doi: 10.1259/bjr.20180462. Epub 2018 Nov 1.

PMID:
30102561
9.

Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation.

Chitre S, Stölzel F, Cuthill K, Streetly M, Graham C, Dill C, Mohamedali A, Smith A, Schetelig J, Altmann H, Bornhäuser M, Mufti GJ.

Leukemia. 2018 Sep;32(9):2020-2024. doi: 10.1038/s41375-018-0208-8. Epub 2018 Jul 19. No abstract available.

PMID:
30026569
10.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

Dimopoulos M, Weisel K, van de Donk NWCJ, Ramasamy K, Gamberi B, Streetly M, Offidani M, Bridoux F, de la Rubia J, Mateos MV, Ardizzoia A, Kueenburg E, Collins S, Di Micco A, Rosettani B, Li Y, Bacon P, Sonneveld P.

J Clin Oncol. 2018 Jul 10;36(20):2035-2043. doi: 10.1200/JCO.2017.76.1742. Epub 2018 Feb 2.

PMID:
29394124
11.

Guidelines for the use of imaging in the management of patients with myeloma.

Chantry A, Kazmi M, Barrington S, Goh V, Mulholland N, Streetly M, Lai M, Pratt G; British Society for Haematology Guidelines.

Br J Haematol. 2017 Aug;178(3):380-393. doi: 10.1111/bjh.14827. Epub 2017 Jul 5.

PMID:
28677897
12.

Living with the burden of relapse in multiple myeloma from the patient and physician perspective.

Hulin C, Hansen T, Heron L, Pughe R, Streetly M, Plate A, Perkins S, Morgan K, Tinel A, Rodrigues F, Ramasamy K.

Leuk Res. 2017 Aug;59:75-84. doi: 10.1016/j.leukres.2017.05.019. Epub 2017 May 31.

13.

Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.

Maciocia N, Melville A, Cheesman S, Sharpley F, Ramasamy K, Streetly M, Jenner M, Benjamin R, Schey S, Maciocia P, Popat R, D'sa S, Rismani A, Cerner A, Yong K, Rabin N.

Br J Haematol. 2017 Mar;176(6):908-917. doi: 10.1111/bjh.14547. Epub 2017 Feb 17.

PMID:
28211054
14.

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.

Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E, Cavenagh J; Myeloma UK Early Phase Clinical Trial Network.

Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.

15.

Is the revised International staging system for myeloma valid in a real world population?

Walker I, Coady A, Neat M, Ladon D, Benjamin R, El-Najjar I, Kazmi M, Schey S, Streetly M.

Br J Haematol. 2018 Feb;180(3):451-454. doi: 10.1111/bjh.14341. Epub 2016 Oct 13. No abstract available.

PMID:
27734463
16.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG.

Leukemia. 2016 May;30(5):1005-17. doi: 10.1038/leu.2015.356. Epub 2015 Dec 29. Review.

PMID:
26710887
17.

Time to redefine Myeloma.

Pratt G, Bowcock S, Chantry A, Cook G, Jackson G, Lai M, Low E, Mulholland N, Owen R, Rabin N, Ramasamy K, Snowden JA, Streetly M, Wechalekar A, Yong K, Bird J.

Br J Haematol. 2015 Oct;171(1):1-10. doi: 10.1111/bjh.13620. Epub 2015 Jul 27.

PMID:
26221971
18.

Bone marrow assessment in asymptomatic IgM monoclonal gammopathies - reply to Varettoni et al.

Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, Matthey F, McCarthy H, McNicholl FP, Rassam SM, Wagner SD, Streetly M, D'Sa S; British Committee for Standards in Haematology.

Br J Haematol. 2015 Jan;168(2):302-3. doi: 10.1111/bjh.13095. Epub 2014 Aug 27. No abstract available.

PMID:
25160738
19.

Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.

Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, McLornan D, Kazmi M, Marsh J, Kwan J, Huang G, Getzendaner L, Lee S, Guthrie KA, Mufti GJ, O'Donnell P.

Biol Blood Marrow Transplant. 2014 Jun;20(6):890-5. doi: 10.1016/j.bbmt.2014.03.003. Epub 2014 Mar 18.

20.

Guidelines on the diagnosis and management of Waldenström macroglobulinaemia.

Owen RG, Pratt G, Auer RL, Flatley R, Kyriakou C, Lunn MP, Matthey F, McCarthy H, McNicholl FP, Rassam SM, Wagner SD, Streetly M, D'Sa S; British Committee for Standards in Haematology.

Br J Haematol. 2014 May;165(3):316-33. doi: 10.1111/bjh.12760. Epub 2014 Feb 15. No abstract available.

PMID:
24528152
21.

Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.

Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D'Sa S, Rabin N, Johnston R, Schey S, Yong K.

Eur J Haematol. 2013 May;90(5):420-5. doi: 10.1111/ejh.12070. Epub 2013 Mar 14.

PMID:
23294279
22.

Pneumonitis post-haematopoeitic stem cell transplant - cytopathology clinches diagnosis.

Yapa HM, McLornan DP, Raj K, Streetly M, Kazmi M, Cuthill K, Laurie J, Menon PA, Macmahon E.

J Clin Virol. 2012 Nov;55(3):278-81. doi: 10.1016/j.jcv.2012.08.007. Epub 2012 Sep 6.

PMID:
22959064
23.

Re-transplantation after bortezomib-based therapy.

Morris C, Cook G, Streetly M, Kettle P, Drake M, Quinn M, Cavet J, Tighe J, Kazmi M, Ashcroft J, Cook M, Snowden J, Olujohungbe A, Marshall S, Conn J, Oakervee H, Popat R, Cavenagh J.

Br J Haematol. 2011 Jun;153(5):666-8. doi: 10.1111/j.1365-2141.2010.08521.x. Epub 2011 Jan 31. No abstract available.

PMID:
21275960
24.

A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality.

Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K.

Bone Marrow Transplant. 2011 Dec;46(12):1545-50. doi: 10.1038/bmt.2010.347. Epub 2011 Jan 24.

PMID:
21258418
25.

GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.

Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE.

Blood. 2010 May 13;115(19):3939-48. doi: 10.1182/blood-2009-10-251660. Epub 2010 Feb 26.

26.

Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation.

Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA.

Br J Haematol. 2008 Apr;141(1):41-51. doi: 10.1111/j.1365-2141.2008.07013.x.

PMID:
18324965
27.

The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64.

McCarthy DA, Macey MG, Streetly M, Schey SA, Brown KA.

Int Immunopharmacol. 2006 Jul;6(7):1194-203. Epub 2006 Mar 29.

PMID:
16714224
28.
29.

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG.

J Clin Oncol. 2004 Aug 15;22(16):3269-76. Epub 2004 Jul 12.

PMID:
15249589
30.

Supplemental Content

Loading ...
Support Center